Catalent Pharma Solutions
Catalent’s offering in the field of drug delivery is vast and spans inhalable, injectable and oral routes, among others. It is a development, delivery and supply partner with a large range of solutions for small molecules and biotherapeutics, including numerous proprietary drug delivery technologies.
Catalent’s offering in the field of drug delivery is vast and spans inhalable, injectable and oral routes, and others. It is a development, delivery and supply partner with a large range of CDMO solutions for small molecules and biotherapeutics, including numerous proprietary drug delivery technologies.
In February 2024, Novo Holdings A/S (the Novo Nordisk Foundation’s wholly owned holding company) agreed to acquire Catalent for US$16.5 billion.